billHJRES186Event Thursday, May 14, 2026Analyzed

Congressional Apportionment Amendment Deadline Act

Neutral

Summary

HJRES186 is a procedural joint resolution that would impose a ratification deadline of December 31, 2026, on the Congressional Apportionment Amendment, a proposed constitutional amendment from the 1780s that has never been ratified. The bill is in early legislative stages and contains no spending, tax provisions, or regulatory changes that would affect any publicly traded company.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HJRES186 is a procedural constitutional amendment deadline bill with zero funding or economic impact.
  • 2.No publicly traded company is affected by this legislation.
  • 3.The bill is in early legislative stages and faces significant hurdles to passage.

Market Implications

This bill has no market implications. It does not authorize spending, change regulations, impose taxes, or create any contract opportunities. Retail investors should not adjust any positions based on this legislation.

Full Analysis

On May 14, 2026, Representative Darrell Issa (R-CA) introduced HJRES186, the Congressional Apportionment Amendment Deadline Act. The bill was referred to the House Committee on the Judiciary. This joint resolution seeks to establish a ratification deadline of December 31, 2026, for the Congressional Apportionment Amendment, a proposed amendment to the U.S. Constitution that was originally sent to the states in 1789 but has never been ratified by the required three-fourths of states. The bill contains no authorization or appropriation of funds. It is a purely procedural measure that would set a time limit on the ratification process for a centuries-old proposed amendment. There is no money trail, no tax change, no regulatory mandate, and no contract opportunity associated with this legislation. Because the bill does not affect any industry, sector, or company's revenue, costs, or competitive position, there are no structural winners or losers in the public equity markets. The legislative path forward is uncertain; as an early-stage bill in a committee with no reported markup schedule, it faces long odds of passage. Even if enacted, the bill would have zero economic impact on any publicly traded company. No real market data is provided, and no market movements are associated with this bill. The competitive landscape for all sectors remains unchanged.